Last $8.40 USD
Change Today +0.035 / 0.42%
Volume 218.2K
AFFX On Other Exchanges
As of 12:20 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. and BioDiscovery, Inc. Launches New Analysis Software, Nexus Copy Number

Affymetrix and BioDiscovery, Inc. announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan(R) Cytogenetics Suite and OncoScan(R) FFPE Assay Kit. CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of Affymetrix cancer portfolio. Researchers have been finding CNVs and copy neutral changes in liquid and solid tumor samples. With the use of Nexus Copy Number, an advanced discovery tool for interrogating large data sets, researchers have been able to identify biomarkers that drive disease progression. The new Nexus Copy Number for Affymetrix software offers researchers a version of the Nexus Copy Number software that is easier to access and has been specifically tailored for Affymetrix' assays.

Affymetrix Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 11:00 AM

Affymetrix Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 11:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Franklin R. Witney, Chief Executive Officer, President and Director, Gavin H. J. Wood, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

Affymetrix Inc. and Leica Biosystems Announce Launch of Fully Automated RNA in situ Hybridization Assays

Affymetrix Inc. and Leica Biosystems announced the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNA(TM) eZ Assays on the Leica BOND RX staining platform. These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues. Dedicated for research use only, the assays provide researchers with a powerful automated solution for drug discovery, translational research, and the development of new diagnostic tests for personalized medicine. The automation significantly reduces hands-on time and assay run time for profiling single-cell gene expression. The Leica BOND RX system automates the staining process, bringing all the benefits of consistency, reduced labor, and speed. This fully automated assay is hands-free from tissue de-waxing to counter staining, and offers high sensitivity, specificity, and reproducibility with easy standardization across laboratories. ViewRNA eZ Assays represent a major technological advancement offering a robust and reliable platform to easily interrogate the function and disease relevance of any expressed genes. Affymetrix' ViewRNA eZ Assays on the Leica BOND RX platform are now available for research applications. The ViewRNA eZ staining protocol is pre-loaded onto the Leica BOND RX, and the staining kit optimized for FFPE samples and probes of choice are available from Affymetrix.

Affymetrix Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Affymetrix Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net loss of $10,474,000 or $0.14 per basic and diluted share on total revenue of $82,971,000 compared to net loss of $15,437,000 or $0.22 per basic and diluted share on total revenue of $77,945,000 reported a year ago. Loss from operations was $8,742,000 compared to $12,206,000 for the same period of last year. Loss before income taxes was $10,202,000 compared to $14,762,000 for the same period of last year. Non-GAAP net income was $1,904,000 or $0.03 per basic and diluted share compared to non-GAAP net loss of $856,000 or $0.01 per basic and diluted share reported a year ago.

Enzo Biochem Announces Settlement Agreement with Affymetrix

Enzo Biochem Inc. along with its subsidiary Enzo Life Sciences Inc. entered into a settlement with Affymetrix Inc. with respect to actions between the company and Affymetrix before the U.S. District Court, Southern District of New York, Cases No 03-CV-8907 and 04-CV-1555. As a result of the Agreement in settlement of the cases, Affymetrix will pay $5,100,000. Enzo's release of Affymetrix Inc. does not include the litigation currently pending against Affymetrix Inc. in the District of Delaware and any of the claims there asserted.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $8.40 USD +0.035

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abcam PLC 412.25 GBp -3.00
Enzo Biochem Inc $5.10 USD -0.03
Fluidigm Corp $27.88 USD -0.46
Luminex Corp $17.47 USD +0.37
Pacific Biosciences of California Inc $4.72 USD -0.78
View Industry Companies

Industry Analysis


Industry Average

Valuation AFFX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at